Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Non-Muscle Invasive Bladder Neoplasms

Cholangiocarcinoma

Carcinoma, Hepatocellular

Lung Neoplasms

Biliary Tract Neoplasms

Advanced Biliary Tract Carcinoma

Hepato Cellular Carcinoma

Leukemia, Lymphocytic, Chronic, B-Cell

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Colorectal Neoplasms

Lung Neoplasms

Gastroesophageal Adenocarcinoma

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Lung Neoplasms, Small Cell Lung Carcinoma

Limited Stage Small Cell Lung Cancer

Carcinoma, Hepatocellular, Cholangiocarcinoma

Lung Neoplasms

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Fibrolamellar hepatocellular carcinoma, Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Hepatocellular

Adenocarcinoma Of Esophagus, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Adenocarcinoma, Stomach Neoplasms

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular, Liver Cirrhosis

Extensive Stage Small Cell Lung Cancer

Brain Neoplasms, Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Non Small Cell Lung Cancer NSCLC

Urinary Bladder Neoplasms

Biliary Tract Neoplasms, Cholangiocarcinoma

Carcinoma, Hepatocellular

Lung Neoplasms

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Non-small-cell Lung Cancer Patients

Cholangiocarcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Clinical Trials

ADAPT-BLADDER

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

ENHANCE

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

MINUTE

TACTIC

IIT2025-03-YANG-LIFT-HCC

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

I-SPY

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

HAIC-quad

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

TIGOS-LS

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

ALICE

SIENNA

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

CAMILLA

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

NOVOCURE

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

SOLARA

CONCORDE

AUSTRAL

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

DIAMOND

ZENOBIA